Takeda Gets Approval for FRUZAQLA in Japan for Advanced Colorectal Cancer
Takeda (TSE:4502/NYSE) has announced that the Japanese Ministry of Health, Labour and Welfare has approved the manufacture and marketing of FRUZAQLA Capsules (1mg/5mg), containing fruquintinib, a selective oral inhibitor targeting…
Rituxan Approved for Steroid-Resistant Nephrotic Syndrome
Zenyaku Kogyo Co., Ltd. (Japanese-only website) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) have announced that Zenyaku has received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW)…
Roche Unveils First Test with TAGS Tech for Detecting 12 Respiratory Viruses
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its new cobas® Respiratory flex test, the first to incorporate Roche’s proprietary TAGS (Temperature-Activated Generation of Signal) technology. This…
Empowering Women Entrepreneurs 2024 BOTOX Cosmetic Grant Launches Crowdfunding
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), proudly announces the next chapter of its 2024 BOTOX® Cosmetic grant program, focused on empowering women entrepreneurs. This phase introduces crowdfunding campaigns…
Lilly’s Kisunla (donanemab-azbt) Receives Approval in Japan for Treating Early Symptomatic Alzheimer’s Disease
The Ministry of Health, Labour and Welfare of Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL injection for IV infusion every four weeks), Eli Lilly and Company’s (NYSE: LLY) treatment…
Arrowhead Pharmaceuticals Seeks Clearance for Phase 1/2a Study of ARO-INHBE in Obesity Treatment
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that it has filed for regulatory approval to launch a Phase 1/2a clinical trial for ARO-INHBE, its investigational RNA interference (RNAi) therapeutic aimed…
ImpriMed Launches AI Cancer Treatment Prediction at EHA-SfPM, Expands Precision Medicine to Humans
a leading precision medicine company utilizing artificial intelligence (AI) to enhance cancer treatment, has announced its expansion into human oncology. Building on its successful work in veterinary oncology, ImpriMed will…
Lantern Pharma Receives FDA Rare Pediatric Disease Designations for LP-184 in Ultra-Rare Children’s Cancers
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven biotech company focused on developing targeted cancer therapies through its proprietary RADR® AI and machine learning platform, announced that the FDA has granted…
GenSight Biologics Announces Interim Financial Results for H1 2024 and Shares Business Updates
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has released its…
Catherine Owen Adams Appointed CEO of Acadia Pharmaceuticals, Succeeding Steve Davis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the appointment of Catherine Owen Adams as its new Chief Executive Officer (CEO), succeeding Steve Davis. Adams will also join the company’s Board…
WHO Endorses CINtec PLUS Test, Highlighting Roche’s Role in Cervical Cancer Care
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the World Health Organization (WHO) has included dual-stain cytology testing in its updated cervical cancer prevention guidelines. The Roche CINtec® PLUS Cytology…
Pearsanta Partners with Evofem for U.S. Endometriosis Diagnostic Launch in Mid-2025
Aditxt, Inc. (NASDAQ: ADTX), an innovation-driven company focused on accelerating healthcare advancements, announced today that its majority-owned subsidiary, Pearsanta, Inc., has entered into a Market Development Collaboration Agreement with Evofem…